Showing results (61-70 of 342) with videos related to
Sort By:
Pageof 35
Clinical Pharmacokinetics|March 1, 1987
Pharmacokinetics of anticancer drugs in childrenW R Crom, A M Glynn-Barnhart, J H Rodman, et al.Pharmacogenetics|April 1, 1996
Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacksC L Chen, Q Liu, M V RellingThe Journal of Clinical Investigation|November 1, 1994
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemiaT W Synold, M V Relling, J M Boyett, et al.Pharmacogenetics|October 1, 1991
Mephenytoin phenotyping: lack of haematologic effect and timing of urine collectionsM V Relling, D Ayers, R L HeidemanLeukemia|October 10, 1998
Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemiaM H Woo, L J Hak, M C Storm, et al.Blood|February 25, 1999
Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulationV M Belkov, E Y Krynetski, J D Schuetz, et al.Clinical Pharmacology and Therapeutics|August 8, 2008
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemiaG Stocco, M H Cheok, K R Crews, et al.Leukemia|November 13, 2010
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivityS-H Chen, W Yang, Y Fan, et al.Leukemia|August 11, 1998
Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemiaJ E Rubnitz, M V Relling, P L Harrison, et al.Clinical Pharmacology and Therapeutics|April 20, 2013
Clinical implementation of pharmacogenetics: more than one gene at a timeJ A Johnson, T E Klein, M V RellingPageof 35